CONTENT HUB
Latest news
Here, you will find announcements, advancements in synthetic DNA technology, and insights into our contributions to the fields of vaccines, gene therapy, cell therapy and gene editing
4basebio strengthens board with strategic appointment of biopharma leader Dr. Manja Boerman
28 JUL 2025
Press release: 4basebio appoints Dr. Manja Boerman to its Board of Directors
Influenza Research Consortium announces £1.2 million (C$2.2 million) in funding for the development of a novel broad-spectrum vaccine
07 JUL 2025
Press release: 4basebio plc, ConserV Bioscience Limited, Pegasus Biotech, the University of Leicester, and the National Research Council of Canada (NRC) receive funding to develop and manufacture a broadly protective influenza vaccine
4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies
01 JUL 2025
Press release: 4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies
4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNA
02 APR 2025
Press release: MHRA GMP license for 4basebio
4basebio PLC Announces £40.0 million Equity Issuance and £29.4 million Secondary Sale
29 JUL 2024
4basebio PLC Announces £40.0 million Equity Issuance and £29.4 million Secondary Sale
4basebio announces the supply of its opDNA® DNA products into Tier 1 Pharma client’s vaccine program
10 APR 2024
Press release: Supply of opDNA® DNA products into Tier 1 Pharma client’s vaccine program
4basebio announces key milestone with its client progressing into Phase I clinical trials of an mRNA vaccine manufactured from 4basebio’s opDNA®
21 MAR 2024
Press Release: Client progressing into Phase I clinical trials of an mRNA vaccine manufactured from 4basebio’s opDNA®
4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI’s tender process for supplying its RNA Centre of Excellence
1 MAR 2024
Press Release: Tender too deliver research and GMP-grade synthetic DNA in CPI’s tender process
4basebio receives grant to advance its synthetic DNA platform and Hermes® nanoparticle platform for the development of thermostable nucleic acid vaccines
1 AUG 2023
Press Release: Grant to advance synthetic DNA and Hermes® nanoparticle platform